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LETTER TO THE EDITOR
Evaluation of stapler hepatectomy in laparoscopic
liver resection
Buell et al. compared electrosurgical division with stapler division
of hepatic parenchyma during laparoscopic hepatectomy in a
cohort of 1499 patients from 10 centres contributing to a central
database.1 The choice of technique was determined by the surgeon
in question and the study design was non-randomized and retro-
spective. The outcome measures included recurrence-free and
overall survival in cancer patients with and without cirrhosis. The
authors conclude in their abstract that ‘equivalent recurrence and
survival rates were observed’ and assert in the discussion that ‘this
study supports SH [stapler hepatectomy] as a safe and efficacious
technique’.1
These conclusions are not well supported by the data presented
in the paper. Survival analysis is reported for only a subset of the
cancer patients (those with equivalently sized lobar resections, as
cited in Table 21) and thus the number of cancer patients included
in the analysis amounts to only 309 of a total of 761. Survival
analysis was performed separately for non-cirrhotic and cirrhotic
patients, further reducing the sample size in each subgroup. The
Kaplan–Meier curves (Fig. 11) are based on these selected sub-
groups and show numerically inferior survival in the group
undergoing stapler hepatectomy (SH). The differences in survival
are of sufficient magnitude to be clinically important; however,
the sample size was insufficient to reach a conventional signifi-
cance threshold.
Buell et al.1 use these data to claim that recurrence and survival
are ‘equivalent’ in electrosurgical resection (ER) and SH. However,
lack of a statistically significant difference is not the same thing as
equivalence and a much more rigorous study design and analysis
are required to demonstrate equivalence.2 Buell et al.1 have made a
classic type II error by rejecting a hypothesis that may be true,based
on an underpowered analysis. The P-values for the four log-rank
tests corresponding to the survival curves in Fig. 11 range from
0.118 to 0.29. A log-rank test with a P-value of 0.118 (disease-free
survival in non-cirrhotic cancer patients, Fig. 21) does not mean
that there is no difference between SH and ER; it means that the
difference is only significant at an 88% confidence limit. In other
words, the difference is more likely than not to be real. As the
observed differences in survival are clinically significant (about
15%) and the sample size too small to establish whether this is
attributable to chance alone, the claims that the techniques are
equivalent and that SH is‘safe and efficacious’cannot be supported.
Figure 21 also shows 10-year overall and recurrence-free sur-
vival rates in the range of 65–90%, which are unprecedented sur-
vival rates after liver resection for cancer. These findings either
reflect unusual patient selection, in which case they may not be
generalizable, or they raise serious questions about the reliability
of the survival data. Finally, the authors1 state that multivariate
regression analysis did not identify SH as a risk factor for tumour
recurrence. However, there is no evidence that they included
parenchymal transection technique in the multivariate analysis
(Table 31); if they did so, they did not provide the results.
It is more appropriate to conclude that the study1 raises the
possibility of clinically important differences in recurrence and
survival related to SH, but its methods (retrospective, non-
randomized) and analysis were too limited to determine whether
these are real. Clearly, a well-designed, randomized controlled trial
is needed to address the question adequately. In the meantime, the
safety and efficacy of this technique, with respect to recurrence
and survival, should not be assumed.
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